Table 2.
AEs of anti-angiogenesis drugs related studies
| Drugs | Study | Published year | study type | No. of cases | Radiation dose(Gy) | AEs rate(%) |
|---|---|---|---|---|---|---|
| Bevacizumab | Wang C [66] | 2019 | Clinical Trial | 88 | 84 |
> 3Grade: 22 fatal events:11 |
| Lind.J S [68] | 2012 | Clinical Trial | 6 | 66 |
RP:83 > 3Grade: 33 |
|
| Swog S0533 [71] | 2015 | Clinical Trial | 29 | 64 |
> 3Grade: 9.0 fatal events:9.0 |
|
| Endostatin | Zhang S L [73] | 2020 | Meta-analysis | 271 | 60–66 |
RP: ECRT:10.9;ERT:9.4%RE: ECRT:11.6;ERT:12.2 |
| Zhai Y (HELP study) [74] | 2019 | Clinical Trial | 73 | 60–66 |
RP:11.9 > 3Grade: 58.2 5Grade: 2 |
|
| Anlotinib | Baohui H (ALTER 0303) [77] | 2018 | Clinical Trial | 296 | / | Hemoptysis ACC:1.3;SCC10.6 |
| Zhu H [79] | 2022 | Clinical Trial | 7 | 54–66 |
RP:83 fatal events:28.57 |
RP Radiation pneumonitis